Who owns 75886F957 - REGENERON PHARMACEUTICALS - COM - Put based on 13F filings?

Open this security page to review the newest available 13F ownership history, top reported holders, and period-by-period changes.

REGENERON PHARMACEUTICALS - COM - Put Institutional Ownership

Q: What is CUSIP 75886F957?

CUSIP 75886F957 is the security identifier used in SEC filing datasets for 75886F957 - REGENERON PHARMACEUTICALS - COM - Put.

CUSIP: 75886F957

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class: Equity / COM
Price per share: $771.87
All holders as of 31 Dec 2025: Q4 2025
Number of holders: 0

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Investment Quick Answers

What is CUSIP 75886F957?
CUSIP 75886F957 identifies 75886F957 - REGENERON PHARMACEUTICALS - COM - Put in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Continue Investment Research

Latest 13F filings for new institutional portfolio disclosures.
Latest Schedule 13D/13G reports for activist and beneficial ownership updates.
Latest 10-Q/10-K reports to cross-check issuer fundamentals.
Recent insider transactions for management buying/selling context.
SEC investors directory and top value investors for manager-level discovery.
All institutional ownership pages to compare adjacent CUSIP pages.

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP 75886F957:

Q4 2025 (0 holders) Q3 2025 (0 holders) Q2 2025 (0 holders) Q1 2025 (0 holders) Q4 2024 (0 holders) Q3 2024 (0 holders) Q2 2024 (0 holders) Q1 2024 (0 holders) Q4 2023 (0 holders) Q3 2023 (0 holders)

As of 31 Dec 2025, 0 institutional investors reported holding shares of REGENERON PHARMACEUTICALS - COM - Put.

Institutional Holders of REGENERON PHARMACEUTICALS - COM - Put across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Price (Median)	Investors
2025 Q4				$169,116,717	$771.87	0
2025 Q3				$142,647,853	$562.27	0
2025 Q2				$105,367,500	$525.00	0
2025 Q1				$72,777,096	$634.23	0
2024 Q4				$105,327,629	$712.33	0
2024 Q3				$120,736,912	$1051.24	0
2024 Q2				$102,101,881	$1051.03	0
2024 Q1				$129,729,707	$962.49	0
2023 Q4				$308,252,843	$878.29	0
2023 Q3	0	$0	-$8,119,000	$159,393,544	$822.96	0
2023 Q2	11,300	$8,119,000	+$4,885,770	$238,102,001	$718.54	1
2023 Q1	4,500	$3,697,000	+$3,697,000	$332,492,696	$821.67	1
2022 Q4				$140,401,150	$721.49	0
2022 Q3	0	$0	-$413,000	$123,030,000	$688.86	0
2022 Q2	700	$413,000	+$413,000	$96,709,000	$591.13	1
2022 Q1				$38,273,000	$698.40	0
2021 Q4	0	$0	-$1,573,000	$76,034,000	$631.51	0
2021 Q3	2,600	$1,573,000	+$1,573,000	$51,677,000	$605.14	1
2021 Q2	0	$0	-$3,264,000	$33,847,000	$558.52	0
2021 Q1	6,900	$3,264,000	+$3,264,000	$26,590,000	$473.10	1
2020 Q4	0	$0	-$1,903,000	$88,591,000	$483.11	0
2020 Q3	3,400	$1,903,000	+$1,903,000	$52,246,000	$559.77	1
2020 Q2				$95,168,000	$623.65	0
2020 Q1				$69,423,000	$488.30	0
2019 Q4				$89,853,000	$375.48	0
2019 Q3				$47,421,000	$277.41	0
2019 Q2				$59,100,000	$313.00	0
2019 Q1				$44,997,000	$410.61	0
2018 Q4	0	$0	-$1,010,000	$139,587,000	$373.51	0
2018 Q3	2,500	$1,010,000	+$1,010,000	$140,333,000	$404.03	1
2018 Q2				$142,561,000	$344.99	0
2018 Q1				$85,936,000	$344.36	0
2017 Q4				$126,861,000	$375.96	0
2017 Q3				$136,655,000	$441.11	0
2017 Q2				$109,801,000	$491.13	0
2017 Q1				$82,818,000	$387.52	0
2016 Q4				$165,562,000	$827.86	0
2016 Q3				$134,138,000	$402.03	0
2016 Q2				$214,392,000	$349.24	0
2016 Q1				$166,173,000	$360.44	0
2015 Q4	0	$0	-$2,484,000	$181,647,000	$542.87	0
2015 Q3	60,100	$2,484,000	+$2,484,000	$177,843,000	$465.14	1
2015 Q2				$160,956,000	$510.13	0
2015 Q1				$123,460,000	$451.48	0
2014 Q4				$104,157,843	$410.26	0
2014 Q3				$124,806,000	$360.52	0
2014 Q2				$103,695,000	$282.46	0
2014 Q1				$96,869,000	$300.28	0